Prospective Cohort Study on the Effects and Tolerability of Flutamide in Patients with Female Pattern Hair Loss

  title={Prospective Cohort Study on the Effects and Tolerability of Flutamide in Patients with Female Pattern Hair Loss},
  author={Roberto Paradisi and Eleonora Porcu and Raffaella Fabbri and Renato Seracchioli and Cesare Battaglia and Stefano Venturoli},
  journal={Annals of Pharmacotherapy},
  pages={469 - 475}
Background Flutamide has been rarely used (or the treatment of female pattern hair loss (FPHL). Flutamide treatment for FPHL has not been evaluated in long-term studies with sufficiently large numbers of women. Objective: To evaluate long-term effects, safety, and tolerability of flutamide in women with FPHL. Methods: A prospective cohort study was conducted in our tertiary care university hospital. The cohort included 101 women diagnosed with FPHL from January 1991 to January 2006. These women… 

Figures and Tables from this paper

Long-term satisfaction and tolerability with low-dose flutamide: a 20-year surveillance study on 120 hyperandrogenic women
Flutamide is very effective for hirsutism treatment; however, adverse effects are very frequent and affect compliance.
Oral bicalutamide for female pattern hair loss: A pilot study
Antiandrogen therapy with flutamide was useful for the treatment of FPHL with a mean improvement in Ludwig scores about 15 to 28% in 6 to 24 months, although adverse effects limited this therapy.
Ovulatory effects of flutamide in the polycystic ovary syndrome
The study suggests that Flu is a satisfactory therapeutic regimen of the chronic anovulation and the irregularities of the menstrual cycle in hyperandrogenic PCOS patients in the long run.
Androgenetic Alopecia: An Evidence-Based Treatment Update
An assessment of the evidence quality of current publications indicates that oral finasteride and topical minoxidil are the best treatments of androgenetic alopecia.
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
Treating androgenetic alopecia therapy remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, compliance, budget, extent of hair loss, and aesthetic goals, independent of potential financial benefits to the practitioners.
Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version
The purpose of the guideline is to provide dermatologists with an evidence‐based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.
Androgenetic alopecia in women and men: Italian guidelines adapted from European Dermatology Forum/European Academy of Dermatology and Venereology guidelines.
  • A. Alessandrini, M. Starace, B. Piraccini
  • Medicine, Biology
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • 2020
This guideline for the treatment of androgenetic alopecia has been developed by an Italian group of experts taking into account the Italian pharmacological governance and summarizes evidence-based and expert-based recommendations (S3 level).
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
OBJECTIVE To determine the current state of knowledge and provide evidence-based recommendations that could be valid for all specialists taking care of female pattern hair loss (FPHL), a common form
Avaliação citopatológica da mucosa vaginal de camundongas tratadas com um antiandrogênico
Significant alterations were not observed in the estrous cycle phases duration of the mice treated with flutamide, however more studies should be made for being affirmed with certainty the existence or not of effects on the cycle, once that several factors might have been limiting for the emergence of the noxious effects.


Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period.
Flu is a satisfactory therapeutic regimen for any form of hirsutism in the long run, and the use of very low doses of Flu is associated with minimal side-effects and high compliance.
Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period
Very low-dose Flu as a first-line therapy for women with acne and seborrhea is supported, and the maximum drug effect was observed after 1 year, and it was maintained during the following years of treatment.
Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial.
Flutamide at 125 mg daily during 12 months was the minimum effective dose to diminish hirsutism in patients with polycystic ovary syndrome or with idiopathic hirsUTism.
Finasteride Treatment of Hair Loss in Women
Although objective evidence of efficacy is limited, finasteride may be considered for treatment of female pattern hair loss in patients who fail topical minoxidil treatment, and treatment is contraindicated in pregnancy, due to known teratogenicity.
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
In postmenopausal women with AGA, finasteride 1 mg/day taken for 12 months did not not increase hair growth or slow the progression of hair thinning.
Treatment of hyperandrogenic alopecia in women.
Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women
No evidence for hepatotoxicity is found in 190 hyperandrogenic girls or young women receiving low- or ultralow-dose flutamide for up to 54 months, which may represent a first step in a long process whereby the status of low- and ultralowing-doseFlutamide may gradually evolve from 'absence of evidence on toxicity' towards 'evidence of absence of hepatic toxicity'.
A review of hormonal therapy for female pattern (androgenic) alopecia.
The role and place of anti-androgentic agents in female androgenetic alopecia in both pre and post-menopausal women remains to be fully defined and the need for effective agents is highlighted by the paucity of effective treatments and the substantial psychosocial impact of alopECia on women.